GlobeNewswire: Cesca Therapeutics Inc. Contains the last 10 of 215 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T03:57:57ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/08/30/1563351/0/en/Cesca-Therapeutics-to-Present-at-the-H-C-Wainwright-20th-Annual-Global-Investment-Conference.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference2018-08-30T12:30:00Z<![CDATA[RANCHO CORDOVA, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Chris Xu, PhD, chief executive officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 11:40am ET. The conference is being held September 4-6 at the St. Regis in New York City.]]>https://www.globenewswire.com/news-release/2018/08/29/1558281/0/en/Cesca-Therapeutics-Announces-Poster-Presentation-at-the-4th-Annual-CAR-TCR-Summit.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics Announces Poster Presentation at the 4th Annual CAR-TCR Summit2018-08-29T12:30:00Z<![CDATA[Management Will Also Deliver Spotlight Presentation During the “Tech Slam at the Innovation Hub” Management Will Also Deliver Spotlight Presentation During the “Tech Slam at the Innovation Hub”]]>https://www.globenewswire.com/news-release/2018/08/13/1551134/0/en/Cesca-Therapeutics-Announces-Second-Quarter-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update2018-08-13T20:05:00Z<![CDATA[Conference Call to be Held at 4:30 p.m. ET (1:30 p.m. PT) Conference Call to be Held at 4:30 p.m. ET (1:30 p.m. PT)]]>https://www.globenewswire.com/news-release/2018/08/06/1547417/0/en/Cesca-Therapeutics-to-Announce-Financial-Results-for-the-Second-Quarter-Ended-June-30-2018-and-Host-Conference-Call-on-August-13.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2018 and Host Conference Call on August 132018-08-06T12:30:00Z<![CDATA[RANCHO CORDOVA, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the second quarter ended June 30, 2018 on Monday, August 13, 2018 after the close of trading. A conference call and webcast will follow at 4:30 p.m. EDT (1:30 p.m. PDT).]]>https://www.globenewswire.com/news-release/2018/07/16/1537599/0/en/Cesca-Therapeutics-Announces-the-Launch-of-its-PXP-System-for-Automated-Processing-of-Bone-Marrow-Cells.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics Announces the Launch of its PXP™ System for Automated Processing of Bone Marrow Cells2018-07-16T12:30:00Z<![CDATA[PXP consistently delivers high target cell recovery rates with minimal red blood cell (RBC) contamination PXP consistently delivers high target cell recovery rates with minimal red blood cell (RBC) contamination]]>https://www.globenewswire.com/news-release/2018/06/06/1517652/0/en/Cesca-Therapeutics-Announces-Exhibition-at-The-Orthobiologic-Institute-s-9th-Annual-PRP-Regenerative-Medicine-Symposium.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics Announces Exhibition at The Orthobiologic Institute’s 9th Annual PRP & Regenerative Medicine Symposium2018-06-06T12:30:00Z<![CDATA[Company’s device subsidiary, ThermoGenesis, to exhibit its novel PXP™ cellular processing system at Booth 208 Company’s device subsidiary, ThermoGenesis, to exhibit its novel PXP™ cellular processing system at Booth 208]]>https://www.globenewswire.com/news-release/2018/06/04/1516205/0/en/Cesca-Therapeutics-Announces-Reduction-in-Operating-Expenses.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics Announces Reduction in Operating Expenses2018-06-04T12:30:00Z<![CDATA[RANCHO CORDOVA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that it is reducing its US and India workforce by approximately 25%, to a total of 60 full-time equivalent employees, under a plan to be substantially completed by the end of June. This reduction is designed to lower operating expenses while the Company focuses on driving growth of revenue-generating products, while at the same time continuing to develop and commercialize the CAR-TXpress™ cellular processing platform and related X-Series™ products. Affected employees are being offered severance.]]>https://www.globenewswire.com/news-release/2018/05/23/1510788/0/en/Cesca-Therapeutics-Chief-Technology-Officer-Phil-Coelho-Provides-Deep-Dive-into-the-CAR-T-Manufacturing-Process-in-Cell-Gene-Therapy.html?f=22&fvtc=4&fvtv=16649Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR-T Manufacturing Process in Cell & Gene Therapy2018-05-23T12:30:00Z<![CDATA[Wide-ranging interview discusses the shortcomings of the current CAR-T manufacturing process and the significant benefits of automation with CAR-TXpress™ Wide-ranging interview discusses the shortcomings of the current CAR-T manufacturing process and the significant benefits of automation with CAR-TXpress™]]>https://www.globenewswire.com/news-release/2018/05/18/1508942/0/en/Cesca-Announces-Closing-of-5-5-Million-Public-Offering.html?f=22&fvtc=4&fvtv=16649Cesca Announces Closing of $5.5 Million Public Offering2018-05-18T15:12:00Z<![CDATA[RANCHO CORDOVA, Calif., May 18, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the completion of its previously announced public offering of 9,166,667 units (the “Units”), with each Unit consisting of one common share, $0.001 par value (the “Common Shares”) or Common Share equivalent and one common warrant to purchase one Common Share (the “Warrants”) for aggregate gross proceeds of $5.5 million.]]>https://www.globenewswire.com/news-release/2018/05/16/1507591/0/en/Cesca-Prices-5-5-Million-Public-Offering.html?f=22&fvtc=4&fvtv=16649Cesca Prices $5.5 Million Public Offering2018-05-16T16:00:14Z<![CDATA[RANCHO CORDOVA, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced the pricing of its public offering of 9,166,667 units (the “Units”), with each Unit consisting of one common share, $0.001 par value (the “Common Shares”) or Common Share equivalent and one common warrant to purchase one Common Share (the “Warrants”). Cesca is offering the Units at a price of $0.60 per Unit.]]>